International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

IATDMCT Elections 2017

Candidates for the 2017-2019 IATDMCT Council

A password to access the election system has been sent to all active IATDMCT members by email.
If you did not receive your password, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. for assistance.

communications 250x133Click here to cast your ballot
Deadline for voting is June 30, 2017.

 


van Gelder 150x200

IATDMCT President
Not open for nomination: Current President-Elect will become the IATDMCT President

Teun van Gelder
Rotterdam, Netherlands

[+] View Bio

Employment

  • 2010- Professor in Clinical Pharmacology
    Internist-clinical pharmacologist, Dept Hospital Pharmacy, Erasmus Medical Center - Rotterdam - NL
    Internist-nephrologist, Dept Internal Medicine, Erasmus Medical Center - Rotterdam - Netherlands
  • 2002-2010 Internist-clinical pharmacologist, Dept Hospital Pharmacy
    Internist-nephrologist, Dept Internal Medicine
    Both at Erasmus Medical Center - Rotterdam - The Netherlands
  • 2000-2002 Head of the Renal Transplantation Unit - Dept Internal Medicine - Erasmus Medical Center
  • 1998-1999 Post-doctoral fellow Dept Cardiothoracic Surgery -
    Laboratory for Transplantation Immunology, Stanford University - Palo Alto - USA
  • 1996-1998 Internist-nephrologist, Erasmus Medical Center - Rotterdam - The Netherlands
  • 1993-1996 Internist, Erasmus Medical Center - Rotterdam - The Netherlands
  • 1988-1993 Resident Internal Medicine, Erasmus Medical Center - Rotterdam - The Netherlands
  • 1987-1988 MD in (mandatory) Military Service

Education & Certification

  • Clinical Pharmacology (certification: December 1, 2003)
    Trained at University Medical Center Nijmegen – Netherlands in 2002-2003
  • Post-doctoral fellowship (Transplantation Immunology)
    Stanford University 1998-1999 (Professor Randall E Morris)
  • Thesis (Erasmus University Rotterdam) date : May 15, 1996 PhD. Title of thesis "The role of anti Interleukin-2 receptor monoclonal antibody (BT563) in the prevention of acute rejection after organ transplantation"
  • Nephrology (certification April 16, 1996)
    Trained at University Hospital Rotterdam 1995-1996
  • Internal Medicine (certification May 1, 1993)
    Trained at University Hospital Rotterdam 1988-1993
  • Medicine (certification as MD at Feb 20, 1987)
    Trained at Erasmus University Rotterdam 1980-1987 MD

Professional Activities

  • Since 2003 member of IATDMCT.
  • From 2005-2009 Councilor of IATDMCT
  • From 2009-2013 Director of Education within Council of IATDMCT
  • From 2009-2013 Chair of Immunosuppressive drugs committee of IATDMCT
  • From 2009 - 2015 Secretary of Dutch Transplantation Society
  • Since 2011 Chairman of Dutch Society for Clinical Pharmacology and Biopharmacy

Web-of-Science: 346 publications, H-index 39, with 6079 citations (as of March 2015)
Speaker at numerous conferences, both national and international.

Awards

  • 1994 Nephrology Award (Dutch Society for Nephrology)
  • 1996 Jon J. van Rood Award (Dutch Transplantation Society)
  • 1997 Young Investigator Award (European Society Heart Lung Transplantation)
  • 1998 International Young Investigator Award (American Society Transplant Physicians)
  • 2000 International Young Investigator Award (American Society of Transplantation)
  • 2005 Outstanding Speaker Award (American Association for Clinical Chemistry)
  • 2009 Visiting Professor Nephrology West China Medical School Chengdu (China)
  • 2010 Visiting Professor (Kathleen Valles Chair) St George’s Medical School London (UK)
  • 2011 Teacher of the year award (medical students – Erasmus University Rotterdam)

Vision Statement

Therapeutic drug monitoring and analysis+consulting for clinical toxicology are forms of personalized medicine “avant la lettre”. IATDMCT has promoted the individualization of treatment before the term personalized medicine had even been invented. Our strength is the analytical expertise and translation of laboratory results into practical treatment recommendations . My mission will be to promote the added value of our contribution, to increase the visibility of IATDMCT and to increase involvement of clinicians into our Association. 


Langman 150x200

IATDMCT Past President
Not open for nomination; Current President will become the Past President.

Loralie Langman
Rochester MN, USA

[+] View Bio

Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.

Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.

Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.

She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.


Tanigawara Yusuke 150x200

IATDMCT President-Elect

Yusuke Tanigawara
Tokyo, Japan

[+] View Bio

Employment

  • 1998-present, Professor, Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Japan
  • 1998-2007, Director of Hospital Pharmacy, Keio University Hospital, Japan
  • 1993-1998, Associate Professor and Vice Director, Department of Pharmacy, Kobe University Hospital, Japan
  • 1991-1992, Honorary Research Fellow, School of Pharmacy, University of Manchester, U.K.
  • 1990-1993, Lecturer, Department of Pharmacy, Kyoto University Hospital
  • 1985-1990, Instructor, Department of Pharmacy, Kyoto University Hospital

Education & Certification

  • JSPHCS-certified Senior Oncology Pharmacist (JSOP), Japanese Society of Pharmaceutical Health Care and Sciences
  • Board Certified Oncology Pharmacy Specialist (BCOPS), Japanese Society of Hospital Pharmacists
  • Board Certified Supervisor Pharmacist, Japanese Society of Clinical Pharmacology and Therapeutics
  • Board Certified Pharmacist, Japanese Society of Clinical Pharmacology and Therapeutics
  • Pharmacist License of Japan
  • 1983, Ph.D. from Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
  • 1980, MSc from Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
  • 1978,   BSc from Faculty of Pharmaceutical Sciences, Kyoto University, Japan

Professional Activities

  • 2013-2017, IATDMCT Secretary (2 terms)
  • 2017, Chairman, 15th IATDMCT Congress 2017 in Kyoto
  • 2015-2017, Chair of Scientific Committee “TDM in Oncology”
  • Editorial Board, Therapeutic Drug Monitoring
  • 2005-2011, President, Japanese Society of Therapeutic Drug Monitoring (JSTDM)
  • Plenary Lecturer at 14th Congress of IATDMCT 2015 in Rotterdam
  • Plenary Lecturer at 12th Congress of IATDMCT 2011 in Stuttgart
  • Invited speaker at IATDMCT Regional Meeting in Guangzhou, China, 2016
  • Invited speaker at IATDMCT Regional Meeting in Sibiu, Romania, 2014
  • Invited speaker at IATDMCT Regional Meeting in Beijing, China, 2010
  • Symposium speaker and organizer at the IATDMCT Congresses (Vienna in 1995, Cairns in 1999, Montreal in 2009)
  • Number of peer reviewed original articles: 183
  • Book chapters and Review articles: 250
  • Invited lectures at international conferences: 46
  • Invited lectures at Japanese national conferences: 117
  • Dr. Tanigawara was distinguished as “Highly Cited Researcher” by Thomson Reuters ISI database.  His research interests include clinical pharmacokinetics, pharmacodynamics and pharmacogenomics and their applications to TDM.  He also investigates multi-omics biomarkers by means of MS-based proteomics and metabolomics.

Other academic and professional appointments:

  • 2003-present, Executive Board member, Japanese Society of Therapeutic Drug Monitoring (JSTDM)
  • 2015-present, Executive Board member, Japanese Society of Clinical Oncology (JSCO)
  • 2006-present, President, Population Approach Group in Japan
  • 2016-present, Co-chair, Focus Group “Modeling and Simulation,” International Society for Study of Xenobiotics (ISSX)
  • 2011, Fellow of the Japanese Society for Study of Xenobiotics (JSSX)
  • 2007-2009, Delegate for the Board of Pharmaceutical Sciences, International Pharmaceutical Federation (FIP)
  • 2005-2008 and 2010-2014, Executive Board member, Japanese Society of Clinical Pharmacology and Therapeutics
  • 2008-2016, Executive Board member, Japanese Society of Pharmaceutical Health Care and Science
  • 2007-2009, Executive Board member, The Pharmaceutical Society of Japan
  • 2005-present, Council member, Japanese Society of Clinical Oncology
  • 2007-present, Council member, Japanese Society of Medical Oncology
  • 2009-present, Council member, Japanese Cancer Association
  • 2003-present, Council member, Japanese Society of Chemotherapy
  • 2003-present, Council member, Japanese Society for Pharmacoepidemiology
  • 2002-present, Associated Editor, Cancer Science
  • 2005-present, Editorial Board, Japanese Journal of Clinical Oncology
  • 2010-present, Editorial Board, The Japanese Journal of Antibiotics
  • 1999-2001, Editorial Board, European Journal of Pharmaceutical Sciences

Vision Statement
During last 4 years when I served as Secretary, the number of members remarkably increased from 400 to 600.  This was primarily due to expansion to new regions such as Asia.  I will continue to expand the network worldwide.  The key driver will be evolution of science and technology of TDM and CT.  Education is also important.  Young/Junior members account for 45% of total membership, and it is very important to continuously encourage their activity.


 

IATDMCT Secretary
2 Candidates, 1 to be Elected


McMillin Gwen 150x200

Gwendolyn A. McMillin
Salt Lake City, UT, USA

[+] View Bio

Employment

  • University of Utah, School of Medicine, 2014-Present – Professor of Pathology
  • ARUP Laboratories, 2003-Present – Medical Director, Toxicology and Pharmacogenetics
  • University of Utah, School of Medicine, 2010-2014 – Associate Professor of Pathology
  • University of Utah, School of Medicine, 2004-2010 – Assistant Professor of Pathology
  • ARUP Laboratories, 1996-2001 – Research Scientist and Technical Supervisor
  • University of Utah, College of Pharmacy, 1994-1996 – Senior Scientist and Assistant Professor     

Education & Certification

  • PhD, Pharmacology and Toxicology, University of Utah
  • Post-doctoral fellowship in Clinical Chemistry, University of Utah
  • DABCC, Clinical Chemistry
  • DABCC, Toxicological Chemistry

Professional Activities

  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
    • Member, 2006-Present
    • Clinical Toxicology and Drugs of Abuse Committee, 2011-Present
    • Co-Chair, 2013 Congress
    • Treasurer, 2014-2017
    • Invited Speaker, 2015 Congress
  • American Association for Clinical Chemistry (AACC)
    • Member, 1997-Present
    • Annual Meeting Organizer: Vice-Chair 2016, Symposia Coordinator 2010
    • Speaker at Annual and Regional Meetings: 2005, 2007, 2008, 2009, 2011, 2012, 2013, 2014, 2015, 2016
    • TDM Toxicology Division: Chair (2009-2013), Newsletter Editor (2006-2008), Secretary(2005-2006), Nominating Committee member (2017-Present)
    • AACC Academy (formerly NACB): author of laboratory practice guideines, 2013-2017
  • American Board of Clinical Chemistry(ABCC) Board of Directors: 2017-2012
  • College of American Pathologists (CAP)
    • Speaker at the Annual Meeting: 2007, 2008, 2009, 2012
    • Toxicology Resource Committee, 2012-Present
    • Pharmacogenomics Working Group, 2012-Present
  • Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
    • Member, 2003-Present
    • Speaker at the Annual Meeting: 2003, 2004, 2009, 2012
  • American Society for Clinical Laboratory Science (ASCLS)
    • Speaker at Regional Meetings: 2007, 2009, 2010, 2011, 2012, 2013
  • Mass Spectrometry Applications to the Clinical Laboratory(MSACL)
    • Speaker at the Annual Meeting: 2010, 2012
  • Clinical and Laboratory Standards Institute (CLSI)
    • Author of LMPG on Pain Management Testing, 2013-2017
  • Pharmacogenomics Research Network (PGRN), 2016-Present
  • Clinical Pharmacogenetics Implementation Consortium (CPIC)
    • Scientific Advisory Board, 2017-Present
  • American Society for Clinical Pharmacology and Therapeutics (ASCPT), 2017-Present

Why would you be a good member of IATDMCT Council
My experiences attending and participating in each IATDMCT Congress since 2005 and serving as Treasurer since 2014 have positioned me to be a strong Council member. My work experience in therapeutic drug monitoring, clinical toxicology, pharmacogenomics and my involvement in other relevant professional organizations also adds value to my candidacy.


Shipkova Maria 150x200

Maria Shipkova
Stuttgart, Germany

[+] View Bio

Employment

  • 2003-Present Senior scientist and head TDM/Tox section, Institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany
  • 1999-2002 Resident Dept. of Clinical Chemistry, University Göttingen, Germany
  • 1995-1999 Postdoctoral fellow, Dept. of Clinical Chemistry, University Göttingen, Germany
  • 1992-1995 Resident Dept. of Clinical Chemistry, University Sofia, Bulgaria
  • 1991-1992 Resident Dept. Internal Medicine, University Sofia, Bulgaria

Education & Certification

Academic Degrees

  • Dr. med. University Göttingen, Germany, 2002
  • D-r (BG)., University Sofia, Bulgaria, 1990,

Professional Registrations

  • Fellow European Board of Laboratory Medicine/Medical Biopathology (F.E.B.L.M./M.B.), 2013
  • Clinical Pathology Consultant, 1996

Professional Activities  

Professional Society Memberships

  • Vereinte Deutsche Gesellschaft für Laboratoriumsmedizin und Klinische Chemie (DGKL)
  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
  • Transplantation Society
  • Bulgarian Academy of Sciences and Arts

Publications

108 articles contributed to scientific journals and book chapters on the following topics: therapeutic drug monitoring, drug metabolism, drug toxicity, development and evaluation of analytical methods, organ function tests, biomarkers of drug effects.

Stipends and Awards

  • 2015 Grant from the Federal Ministry of Education and Research “Validation of GcfDNA based diagnostic test to detect organ damage after kidney transplantation”
  • 2011 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Analytical validation of biomarker assays in transplantation medicine
  • 2005 Young Investigator Award of the International Society for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
  • 2004 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Acyl glucoronides of mycophenolic acid
  • 2002  Grant of the University Göttingen, Germany, Acyl glucuronide of mycophenolic acid
  • 1998   Stipend Volkswagen Foundation, Germany, Metabolism of immunosuppressants
  • 1996  Stipend Otvoreno Obschtestvo, Bulgaria, Pharmacokinetics of Taxol
  • 1995  Tempus Phare stipend of the EU, Therapeutic Drug Monitoring

Varia

  • Director of Education IATDMCT (2015 - )
  • Vice-Chair IATDMCT Communication Committee (2011 - )
  • Member of the IATDMCT Biomarkers in transplantation Working Group (2009 - )
  • Coordinator “TDM of Everolimus” Consensus Project (2013-2016)
  • Past-Chair of the IATDMCT Immunosuppressive Drugs Scientific Committee (2013–2015)
  • Past Editor in Chief of the IATDMCT Newsletter “Compass” (2009 – 2015)
  • Member of the LOC of the 11th IATDMCT Congress, 2011, Stuttgart, Germany
  • Member of the Editorial Boards of Therapeutic Drug Monitoring (TDM) and Clinical Mass Spectrometry (CMS)
  • Reviewer of publication for: Journal of Chromatography, Clinical Chemistry, Clinical Biochemistry, Clinica Chimica Acta, Transplant International, etc.

Why would you be a good member of IATDMCT Council

I am member of IATDMCT for >20 years and over the past years was privileged to serve IATDMCT at different positions. Thanks to this wonderful experience I am honored to know many IATDMCT members and hope to have been able to convince with organizational-, communication-skills and persistence.


 McKeown Denise 150x200

IATDMCT Treasurer

Denise Anne McKeown
Glasgow, UK

[+] View Bio

Employment

  • Sep 2012-Present: Forensic Medicine and Science (FMS), University of Glasgow, UK
    Forensic Toxicologist
  • Dec 2002-Sep 2012: Analytical Services International (ASI), St George’s, University of London, UK
    Senior Scientist in Clinical and Forensic Toxicology
  • Jul 2002-Nov 2002: Home Office Scientific Development Branch, Hertfordshire, UK
    Scientific Contractor in Explosives and Drug Detection

Education & Certification

  • Sep 1996-June 2002: University of Strathclyde, Glasgow, UK
    MSci in Forensic and Analytical Chemistry

Professional Activities

  • Member of International Association of TDM & Clinical Toxicology (IATDMCT)
    Jan 2012-Present: Communications Committee (CC) Chair
    (activities coordinated by CC: E-News, Social Media, Blog, Website / Resources Area, Compass etc)
    Oct 2011-Oct 2015: Young Scientist Committee (YSC) Chair
    (coordinated all YS activities: Congress YS workshops/symposia, social events and awards, and all non-Congress educational activities)
    Sep 2007-Oct 2015: Compass Associate Editor
    Apr 2005-Oct 2011: Young Scientist Committee (YSC) Vice-Chair
  • Member of The International Association of Forensic Toxicologists (TIAFT)
  • Member of UK and Ireland Association of Forensic Toxicologists (UKIAFT)
  • Member of London Toxicology Group (LTG)
  • Member of Royal Society of Chemistry (RSC)
  • Invited speaker and presented at national and international meetings
  • Contributed to to several peer-reviewed publications and book chapters
  • Visiting Lecturer, Queen Mary, University of London (Oct-2010-Present)

Why would you be a good member of IATDMCT Council?

For 12 years have been an active member with a successful committee history. During decade as YSC Vice-Chair/Chair, YS membership increased from 8 to 296 members. Founding chair of the very active CC, who are integral to association activities. Would devote same enthusiasm to role as Treasurer given the opportunity.


 

Director of Education
4 Candidates, 3 to be Elected


 Rentsch Katharina 150x200

Katharina Rentsch
Basel, Switzerland

[+] View Bio

Employment

  • Since 2014, Head of Laboratory Medicine, University Hospital Basel, Switzerland
  • Since 2011, Head of the Clinical Chemistry division, University Hospital Basel, Switzerland
  • 2004-2011, Deputy Head of the Institute for Clinical Chemistry, University Hospital Zurich, Switzerland
  • 1994-2011, Head of the laboratory for drug analysis and clinical toxicology, Institute for Clinical Chemistry, University Hospital Zurich, Switzerland
  • 1991-1994, Scientist at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland
  • 1990-1991, Head of the Laboratory for Special Analyses at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland
  • 1989-1990, Scientist at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland

Education & Certification

  • 2012, Adjunct professor („Titularprofessorin“), Medical faculty, University Basel, Switzerland
  • 2010-2016, Adjunct professor („Titularprofessorin“), Medical faculty, University Zürich, Switzerland
  • 2007, Certification as „Clinical Toxicologist GTFCh“
  • 2007, Habilitation for Clinical Chemistry at the Medical Faculty of the University Zürich, Switzerland
  • 2003, Habilitation for Clinical Chemistry at the Department of Chemistry and Applied Biosciences, ETHZ, Zurich, Switzerland
  • 1996, PhD dissertation at the Institute of Pharmaceutical Sciences, ETHZ, Zurich, Switzerland
  • 1991, Certification as “Specialist for Laboratory Medicine” awarded by the FAMH (Swiss Association of the Heads of Medical Laboratories)
  • 1988, Master of Science in Pharmacy, Swiss Federal Institute of Technology Zurich, (ETHZ), Switzerland; awarded pharmacist’s license

Professional Activities

  • International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
  • The International Association of Forensic Toxicologists (TIAFT)
  • American Association for Clinical Chemistry (AACC)
  • Society of Toxicological and Forensic Chemistry (GTFCh)
  • Swiss Society of Clinical Chemistry (SSCC)
  • Swiss Chemical Society (SCS)
  • Swiss Group of Mass Spectrometry (SGMS)
  • Swiss Association of the Heads of Medical Laboratories (FAMH)
  • Swiss Federation of Pharmacists (pharmaSuisse)

Executive and committee positions held

  • Vice president  of the Society of Toxicological and Forensic Chemistry (GTFCh) (since 2015)
  • Member of the GTFCh committee “Clinical Toxicology” (since 2001)
  • Chair of the SSCC committee “Drug Monitoring” (since 2003)
  • President of the Swiss Society of Clinical Chemistry (SSCC) (2009-2014)
  • Vice president of the SSCC and chair of the scientific committee (2006-2008)
  • Member of the board of the Division “Analytical Chemistry” of the Swiss Chemical Society (2006-2008)

Activities for IATDMCT

  • Director of Education of the IATDMCT (since 2015)
  • Councilor of the IATDMCT 2007 – 2015
  • Member of the Clinical Toxicology/Drugs of Abuse Committee (since 2006)
  • Member of the Local Organizing Committee of the Stuttgart Meeting (responsible for roundtables). 2011
  • Member of the Scientific Board of the Basle Meeting (responsible for CT breakfast roundtables), 2003

Number of publications

  • > 150 peer reviewed original papers and invited reviews
  • > 60 published oral or poster presentations
  • 8 book chapters

Speaking engagements

  • > 120 invited lectures (universities, national and international meetings)

Professional appointments

  • Referee of scientific journals (e.g Clin Chem, J Chromatogr A and B, J Mass Spectrom, Anal Bioanal Chem, Anal Chem, Clin Mass Spectrom)
  • Lecturer University Basel, Pharmaceutical Sciences: “Clinical Chemistry” including Therapeutic Drug Monitoring and Clinical Toxicology (3rd year Bachelor, 1st year Master)
  • Lecturer University Basel Medical School: “Chemistry in Blood” (2nd year Bachelor)
  • Lecturer Swiss Federal Institute of Technology (ETHZ), Medical and Industrial Pharmaceutical Scienses: “Bioanalytics” in the module “Clinical research and development” (1st year Master)
  • Lecturer Swiss Federal Institute of Technology (ETHZ), Pharmaceutical Sciences: “Clinical Chemistry” including Therapeutic Drug Monitoring and Clinical Toxicology (3rd year Bachelor, 1st year Master) (until 2012)
  • Lecturer University Zurich Medical School: “Therapeutic Drug Monitoring” (1st year Master) (ongoing), Clinical Toxicology (2nd year Bachelor), Clinical Chemistry (2nd year Bachelor, 1st year Master) (until 2011)

 Rosenborg Staffan 150x200

Staffan Rosenborg
Stockholm, Sweden

[+] View Bio

Employment

  • 2013 – Present Head of Clinical Pharmacology Trial Unit, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
  • 2010 – 2013 Head of Residents and Director of Postgraduate Training, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
  • 2007 – 2010 Consultant Clinical Pharmacologist, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
  • 2004 – 2007 Resident in Clinical Pharmacology, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
  • 1998 – 2003 Resident in Nephrology, Dept of Renal Medicine, Karolinska University Hospital, Stockholm, Sweden

Education & Certification

  • 2016 Diploma in Clinical trials, Swedish Academy of Pharmaceutical Sciences
  • 2010 Ph.D. in Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
  • 2007 Specialist Certificate in Clinical Pharmacology, National Board of Health and Welfare, Sweden
  • 2003 Specialist Certificate in Nephrology, National Board of Health and Welfare, Sweden
  • 1996 Medical Doctor, Karolinska Institutet, Stockholm, Sweden

Professional Activities

  • 2016 – present, National representative in Section of Pharmacology, UEMS (Union Européenne des Médecines Spécialistes)
  • 2015, Invited speech “Implementing the National curriculum in Clinical Pharmacology” at a satellite symposium to the Federation of European Physiological Societies (FEPS) and the Baltic Physiological Societies in Kaunas, Lithuania, August 26-29.
  • 2015 – present, Secretary in the Swedish Foundation of Clinical Pharmacology and Therapeutics
  • 2006 – present, Member of the Stockholm County Council Drug Expert Panel in Renal Medicine
  • 1996 – present, 33 published papers including case reports and clinical trials

Saint Marcoux Franck 150x200

Franck Saint-Marcoux
Limoges, France

[+] View Bio

Employment:

  • Since 2014:
    • Full Professor and Hospital Practitioner at the Limoges University Hospital (France):
      • Full Professor of Toxicology, Faculty of Pharmacy, University of Limoges
      • Hospital Practitioner: Responsible of clinical toxicology, environmental toxicology and forensic science units; department of pharmacology and toxicology
  • From 2007 to 2014:
    • Hospital Practitioner: Responsible of Therapeutic Drug Monitoring and applied pharmacokinetic Unit ; department of pharmacology and toxicology
  • Since 2007:
    • Head of PK/PD modeling and clinical transfer in the  INSERM research unit (French National Institute for Medical Research); Pharmacology of immunosuppressive drugs and transplantation (UMR 850; Director: Pierre Marquet)

Education & Certification:

  • Pharmacy:
    • Qualification as full Professor (2014)
    • State Doctorate of Pharmacy (2004)
    • Internship and post-graduate diploma in clinical chemistry (1999 – 2004)
  • Science:
    • Qualification as a Research Supervisor (2013)
    • Doctoral Thesis in PKPD modeling (2004)
  • Forensic science:
    • Expert at the Court of Appeal (2014)

Professional Activities:

  • Main membership of scientific societies
    • IATDMCT:
      • Chair of the Pharmacometrics committee since 2011 (co-chair from 2009 to 2011)
      • Councillor since 2013
      • Member of the Editorial board of the Compass newsletter since 2015
      • Member of the association since 2005 :  attending international and regional meetings, organizing multiple symposia, workshops, round tables and judging prize awards
    • French Society of Pharmacology and Therapeutics:
      • Member of the administrative council from 2010 to 2014
      • Chair of the TDM Committee from 2010 to 2014
      • Member since 2002
    • French Society of Analytical Toxicology:
      • Member since 2003
  • Main scientific works and awards:
    • Author or co-author of 62 peer-reviewed papers
    • About 50 invited conferences
    • About 75 oral presentations in scientific congresses
    • IATDMCT Patsalos prize 2013
    • ESOT best poster 2009
    • IATDMCT best oral presentation 2007

 vanMaarseveen Erik 150x200

Erik van Maarseveen
Utrecht, The Netherlands

[+] View Bio

Employment

  • University Medical Center Utrecht, The Netherlands
  • The Hague Central Pharmacy, the Netherlands
  • Groene Hart Ziekenhuis Gouda, The Netherlands

Education & Certification

  • Pharmacy degree at Utrecht University, The Netherlands (2005)
  • Certificate of Fundamentals of Business &Economics for Beta’s, Master of Science & Product management, University of Utrecht (2006)
  • Registration as hospital pharmacist (2010)
  • Basic course on Regulations and Organization for clinical investigators (BROK®) (2011)
  • Academic Leadership Training Program (2014/2015)
  • University teaching qualification (2015)
  • Registration as Clinical Pharmacologist (2017)

Professional Activities

  • Member of IATDMCT scientific TDM in Oncology committee
  • Board member of the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology
    (see http://kkgt.nl/?lang=en)
  • Member of the Committee on Analysis and Toxicology of the Dutch Association of Hospital Pharmacists
  • >30 peer-reviewed publications (see https://www.researchgate.net/profile/Erik_Van_Maarseveen2)
  • Oral presentations at European Bone Marrow Transplantation Congress, American Transplant Congress, International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Dutch congress on Clinical Pharmacology, European Solid Organ Transplantation Congress among others.
  • Lecturer at the Faculty of Pharmacy and Medicine, Utrecht University

 

Councilor
10 Candidates, 4 to be Elected


 Alffenaar JanWillem 150x200

Jan-Willem Alffenaar
Groningen, The Netherlands

[+] View Bio

Dr Jan-Willem C Alffenaar started his career in 2002 as pharmacist at the department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen in the Netherlands. From 2005-2008 he served as a hospital pharmacist in residence at the same hospital. During his routine TDM training he developed great interest into infectious diseases. This resulted in a thesis titled “The pharmacokinetics and TDM of antimicrobial agents, in particular antifungal agents and anti-TB drugs”. He finished his thesis in 2009 and has been a Principle Investigator of many clinical studies evaluating clinical pharmacology of antimicrobial drugs since. In 2012 he finished his training in clinical pharmacology and became member of the Ethical Review Board of the University Medical Center Groningen. Dried blood spot analysis got his specific attention as it enables TDM in resource limited settings. In 2013 he was appointed as associate professor at the Medical Faculty of the University of Groningen with the scope of optimizing antimicrobial therapy based on PK/PD principles. He became Editorial Board member of "Therapeutic Drug Monitoring" and “Clinical Mass Spectrometry”. He (co)authored over 140 papers in peer-reviewed scientific journals. At this moment he is supervising 16 PhD and PharmD-PhD student. He received the "young investigator award" from International Association for Therapeutic Drug Monitoring and Clinical Toxicology in 2015.

Employment

  • 2013-present Associate Professor of Medicine
  • 2012 Head of the Laboratory for Clinical Pharmacology, toxicology and therapeutic drug monitoring. Department of Clinical and Hospital Pharmacy, UMCG a.i.
  • 2011- present Principle Investigator: Clinical Pharmacology of Antimicrobial Agents
  • 2009- present Hospital Pharmacist, Department of Clinical and Hospital Pharmacy, UMCG, staff member.
  • 2005-2008 Hospital Pharmacist in residence, Department of Clinical and Hospital Pharmacy, UMCG
  • 2004-2005 Head of logistics of medicine , Department of Clinical and Hospital Pharmacy, University Medical Center Groningen
  • 2002- 2003 Pharmacist, “Proeftuin Farmacie Groningen”. Coördinator Regional Formulary
  • 2002- 2005 Pharmacist, Department of Clinical and Hospital Pharmacy, UMCG.

Education & Certification

  • 2015 University Teaching Qualification (BKO)
  • 2015-2016 Coordination and guidance (management course)
  • 2012 Teach the Teacher
  • 2012 Clinical Pharmacologist, board certification
  • 2011, 2015 GCP certificate
  • 2006-2009 PhD in Medicine. Subject: Pharmacokinetics of antimicrobial agents: optimization and individualization of treatment
  • 2008 Hospital Pharmacist , board certification (incl radiation expertise: 4A+4B)
  • 2004 Management course
  • 2000-2002 PharmD, University of Groningen
  • 1995-2000 MSc in Pharmacy, University of Groningen (incl license 9 to work with animals in medical experiments)

Professional Activities

Memberships

  • Dutch Society of Clinical Pharmacology and Biopharmaceutics
  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology
  • Dutch Association of Hospital Pharmacists
  • Royal Dutch Association of Pharmacists
  • American Society of Microbiology
  • European society of clinical microbiology and infectious diseases

Member of several study groups: International Study Group on carbapenems, International Group for the study of Linezolid

Committees

  • Antimicrobial drugs Committee UMCG (2015-present)
  • Working group: treatment of latent Tuberculosis (2013-present)
  • WHO-ECDC-ERS: expert advisor on clinical pharmacology of TB drugs: (2013-present)
  • Medical and Ethical Review Board UMCG: (2013-present)
  • Member Medication Incident Committee CvR UMCG (2009-2013)
  • Chair committee “New Sampling Strategies”. IATDMCT (2015-2017)
  • Vice Chair committee “New Sampling Strategies”. IATDMCT (2012-2015)
  • Chair committee “Anti-infective drugs Committee”. IATDMCT (2013-2015)
  • Vice Chair committee “Antifungal drugs Committee”. IATDMCT (2010-2013)
  • Member committee “Pharmacometrics”. IATDMCT (2013-present)
  • Member committee “Anti-infective drugs”. IATDMCT (2008-present)

Program leader KKGT: international Quality Control program for bio-analysis of TB drugs. (2011-   )
Program leader KKGT: international Quality Control program for bio-analysis of antifungal drugs. (2008 -  )

Publications: international publications 144, H-index 23
PhD students: 7 finished thesis defenses; 15 are currently being supervised                       
Educational activities: University of Groningen: course Infectious Diseases; supervision of MSc students
Invited lectures/oral presentations: >60
Clinical studies (Principle Investigator): 20
Editorial Board Member: Therapeutic Drug Monitoring, Clinical Mass Spectrometry, Fungal Pharmacology
Award: IATDMCT Victor Armstrong Young Investigator award 2015


Bergan Stein 150x200

Stein Bergan
Oslo, Norway

[+] View Bio

Employment

  • 2007-present: Professor in Pharmacology; School of Pharmacy, University of Oslo
  • 2011-present: Senior Scientist; Section of Clinical Pharmacology Rikshospitalet, Department of Pharmacology, Oslo University Hospital
  • 2009-2015: Head of department/Section leader; Dept of Pharmacology, Oslo University Hospital
  • 1990-2009: (Senior) Scientist; Dept of Medical Biochemistry, Rikshospitalet Medical Centre, Oslo
  • 1989-1990: Hospital Pharmacist; Hospital Pharmacy, Rikshospitalet, Oslo
  • 1982-1989: Hospital Pharmacist; Hospital Pharmacy, Sarpsborg County Hospital
  • 1979-1982: Retail Pharmacist; Community Pharmacy, Moss

Education & Certification

  • 1992-1998  PhD; Doctoral thesis: 'Azathioprine monitoring in renal transplantation.'  Faculty of Medicine, University of Oslo
  • 1992 Specialist in Hospital Pharmacy; The Norwegian Association of Pharmacists
  • 1973-1978 M.Sci.Pharm.; School of Pharmacy, University of Oslo, Norway

Professional Activities

  • Membership: IATDMCT, Europ Assoc Hosp Pharmacists (EAHP), Transplantation Society (TTS), European Soc Organ Transplantation (ESOT), Norw Soc Pharmacology & Toxicology; Norw Assoc Pharmacists; Norw Assoc Hosp Pharmacists
  • Member of IATDMCT scientific committee: Immunosuppressive drugs
  • Number of peer-reviewed publications (Pubmed): 73; Book chapters 3
  • Presentations at a large number of international meetings, chair of symposia, including several IATDMCT congresses; member of scientific committee at several congresses
  • Leader of research group 'Individualizing Immune Modulation and Chemotherapy'; supervised 6 PhD candidates (+3 in progress).
  • Editorial board member of the journal Therapeutic Drug Monitoring; Associate Editor of the European Journal of Hospital Pharmacy;
  • Member of adjudication committee and opponent for doctoral theses, Norway and abroad;  Member of appointment committees (Norway)
  • Lectures and course leadership in master program and continuing education courses for pharmacists and medical specialists

Chen Zhigang 150x200

Zhigang Chen
Beijing, China

[+] View Bio

Education

  • Visiting scholar  Erasmus MC Rotterdam Netherlands,  2011-2012
  • Master of Science in Clinical Pharmacology, Peking University Health Science Center, Beijing, 2001-2005, study experience in Peking Union Medical College Hospital (PUMCH) , Beijing, 2002.9-2003.10
  • Bachelor of Pharmacology, ShenYang Pharmaceutical University, Shenyang, China 1992-1996

Experience and Positions

  • 2014.10-2018.10, Chairman of TDM China Youth Committee
  • 2014.4-Present, Vice-director of clinical study center in Beijing Jishuitan Hospital
  • 2005.12-2014.4, Assistant director of pharmacy department Beijing Jishuitan Hospital
  • 2010-Present, Specialist and trainer of CFDA

Research Interests

  • 2014.10-2018.10,  Chairman, Youth Committee of TDM China
  • 2016-present, Deputy Director-General,  the association of bone and joint surgery of China Geriatrics Society.
  • 2010- present, specialist and trainer of CFDA
  • Published 8 papers in Chinese and 1 paper in English
  • Professional appointments: individualized treatment in osteoporosis patients, the drug phase I-IV and medical device clinical trials in orthopedics and geriatrics especially

Training

  • Clinical coordinator workshop. AO , HongKong,2014
  • Good Clinical Practice Training by SFDA. Beijing, 2000, 2005, 2009
  • Evidence-based medicine training course. Beijing2004
  • Ethics training by SFDA in Xiamen,2009

Awards / Honors

  • Excellent Paper Award, the sixth China Shimadzu Analysis Competition, the second award (2002, Beijing, China).
  • Excellent Paper Award, the second award, the Peking Pharmaceutical Association (2005).

 Lynch Kara 150x200

Kara Lynch
San Francisco, CA, USA

[+] View Bio

Employment:

  • Associate Professor, Department of Laboratory Medicine, University of California, San Francisco (2015 - )
  • Co-Director, Core Laboratory (Chemistry/Toxicology), Zuckerberg San Francisco General Hospital (2009 - )
  • Program Co-Director, COMACC-accredited UCSF Postdoctoral Training Program in Clinical Chemistry (2009 - )
  • Assistant Professor, Department of Laboratory Medicine, University of California, San Francisco (2009 - 2015)
  • Adjunct Professor, University of San Francisco, School of Nursing (2008 - 2009)

Education & Certification:

  • Butler University – Bachelor of Science, Chemistry and Biology (1998 – 2002)
  • University of Wisconsin – Doctor of Philosophy, Biochemistry (2002 – 2007)
  • University of California, San Francisco – Post-doctoral Fellowship (2007-2009)
  • Diplomate of the American Board of Clinical Chemistry – DABCC (2009 – present)
  • Fellow of the National Academy of Clinical Biochemistry (2014 – present)

Professional Activities (including memberships, executive and committee positions held, activities in IATDMCT, number of publications, speaking engagements, professional appointments)

Memberships

  • 2007-present, American Association for Clinical Chemistry (AACC)
  • 2007-present, Northern California Local Section of the American Association for Clinical Chemistry
  • 2007-present, Society of Young Clinical Laboratorians (SYCL)
  • 2008-present, Society of Forensic Toxicology (SOFT)
  • 2008-present, Therapeutic Drug Monitoring and Toxicology Division of the AACC
  • 2009-present, Academy Clinical Laboratory Physicians and Scientists (ACLPS)
  • 2010-present, American Academy of Clinical Toxicology (AACT)
  • 2011-present, International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
  • 2012-present, American Society for Mass Spectrometry (ASMS)
  • 2012-present, Clinical and Diagnostic Immunology Division of the AACC
  • 2013-present, National Academy of Clinical Biochemistry (NACB)
  • 2015-present, Mass Spectrometry and Separation Sciences Division of the AACC

Executive and Committee Positions

  • 2008, AACC Northern California Local Section Secretary
  • 2010, AACC Northern California Local Section Chair-Elect
  • 2011, SYCL 2011 Workshop Committee
  • 2011, AACC Northern California Local Section Chair
  • 2012, AACC Northern California Local Section Past-Chair
  • 2012-2013, Clinical and Diagnostic Immunology Division Secretary
  • 2012-2013, Organizing Committee for the 2013 IATDMCT Conference in Salt Lake City
  • 2012-2014, Organizing Committee for the 2014 ACLPS Conference in San Francisco
  • 2013-2014, AACC Northern California Local Section Nominating Committee
  • 2011-2016, Strategies Online Editorial Advisory Board
  • 2012-2015, AACC Northern California Local Section Delegate
  • 2012-present, Mass Spectrometry Applications to the Clinical Laboratory (MSACL) Scientific Committee
  • 2013-2015, Therapeutic Drug Monitoring and Toxicology Division (AACC) Member-at-large
  • 2013-present, Commissioner for ComACC: the commission on accreditation in Clinical Chemistry
  • 2015-present, Clinical and Forensic Toxicology News (CFTN) Editorial Board
  • 2015-present, AACC Annual Meeting Organizing Committee - AACC 2017, San Diego
  • 2017-present, Therapeutic Drug Monitoring and Toxicology Division (AACC) Chair-elect

Activities in IATDMCT

  • 2012-2013, Organizing Committee for the 2013 IATDMCT Conference in Salt Lake City
  • 2014, Presenter in the IATDMCT Symposium at the AACC Annual Meeting

Number of Publications

  • Peer-reviewed publications – 43
  • Book chapters - 5

Presentations

  • International – 7 (3 at IATDMCT Congresses)
  • National (US) - >40

Marriott D 150x200

Deborah Marriott
Sydney NSW, Australia

[+] View Bio

Current Appointments

  • Senior Specialist in Clinical Microbiology and Infectious Diseases
    St. Vincent's Hospital, Sydney (1985 - to date)
  • Clinical Director, Antimicrobial Therapeutic Drug Monitoring Group
    St. Vincent’s Hospital, Sydney (2012 – to date)
  • Visiting Medical Officer                              
    St. Vincent's Private Hospital, Sydney (1985 – to date)
  • Visiting Medical Officer
    Sacred Heart Hospice, Sydney (1985 – to date)
  • Conjoint Professor, School of Medicine
    University of New South Wales (2000 – to date)
  • Adjunct Professor, Faculty of Science
    University of Technology, Sydney (2002 -to date)

Certifications

  • Fellow of the Royal College of Pathologists of Australasia (FRCPA)
    1986
  • Fellow of the Royal Australasian College of Physicians (FRACP)
    1985
  • Bachelor of Medicine and Bachelor of Surgery
    Honours Class I
    1977
  • Bachelor of Science (Medicine)
    Honours Class I
    1974

Current Memberships - Professional Societies

  • Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia
  • Australasian Society for Infectious Diseases
  • Australasian Society for HIV Medicine
  • American Society for Microbiology
  • Australasian Society for Antimicrobials
  • Infectious Diseases Society of America
  • International Society for Heart and Lung Transplantation
  • International Association for Therapeutic Drug Monitoring and Clinical Toxicology
  • Transplant Infectious Diseases
  • European Society for Clinical Microbiology and Infectious Diseases
  • The Transplant Society
  • Animal Management in Remote and Indigenous Communities

Selection of Professional Activities (all to date unless otherwise indicated)

    • 1986 – Member, Drug and Therapeutics Committee, St. Vincent's Hospital
    • 1988 – Accreditor,  National Association of Testing Authorities
    • 1989 – 97  Member, N.S.W. State Committee, Royal Australasian College of Physicians 
    • 1990 – Examiner, Royal Australasian College of Pathologists
    • 1993 – 2014 Member, Tuberculosis Advisory Committee, N.S.W. Department of Health
    • 1995 Visiting lecturer, University Santo Tomas, Manila, Philippines
    • 1997 – 99 President, Australasian Society for HIV Medicine
    • 2000 – 10 Member, Pharmacology and Toxicology Working Group, National Centre in HIV Epidemiology and Clinical Research
    • 2009 – 13 Co-chair, Australian and New Zealand Mycoses Interest Group
    • 2010 – Examiner, Royal Australasian College of Physicians
    • 2012 – Scientific Committee vice chair (HIV and Infectious Diseases) and Councillor, International Association for   Therapeutic Drug Monitoring and Clinical Toxicology
    • 2012 – Scientific Committee member, Transplant Infectious Diseases
    • 2013 – President, Transplant Infectious Diseases
    • 2013 – Board Member,  Medical Advances without Animals
    • 2014 – Visiting Lecturer, The Academy of Medicine, Singapore
    • 2014 –  Visiting International Professor, Royal College of Pathologists of Australasia
  • Approximately 190 publications in refereed journals
  • Joint lead, IATDMCT Guidelines on TDM of Echinocandins
  • Author, Therapeutic Drug Monitoring of Antifungal Agents Used in Patients Post Cardiothoracic Transplantation or with a Mechanical Circulatory Device.  The 2014 International Society for Heart and Lunch Transplantation Guidelines for Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients.
  • Proposer and Co-Convener –IATDMCT conference, Guangzhou, China, August 2016
  • Keynote and invited speaker at many national and international meetings including ICAAC (Denver 2012), IATDMCT (Salt Lake City 2012), ISHLT (Montreal, 2012; San Diego, 2013), The World Transplant Congress (San Francisco 2014), Transplant Infectious Diseases (Berlin, 2012; Vienna, 2013; Barcelona 2014, Hong Kong 2016), ISHAM (Melbourne 2015),   The 5th and 6th National Annual Conference on Therapeutic Drug Monitoring, China (Beijing 2015, Nanjing 2016)
  • Convener and speaker at a number of regional Mycology Master Classes run under the auspices of the International Society of Human and Animal Mycology (ISHAM) including Phuket (2011), Singapore (2012), Seoul (2013), Penang (2014) and Bangkok (2016).
  • Convener and speaker,  Mycology Master Classes, Australia – 2008-2017 and on-going
  • Extensive connections with the Asian region and an invited speaker at many conferences within Asia, including Malaysia, Hong Kong, Singapore, Indonesia, Japan and China.
  • Coordinator of the Clinical Stream at the ISHAM conference in Melbourne (May 2015) and convener of the pre-congress workshop on Therapeutic Drug Monitoring in Fungal Infections.
  • Reviewer of approximately 15 manuscripts per year for the past 10 years in local and international  journals

Meyer Markus 150x200

Markus Meyer
Stockholm, Sweden

[+] View Bio

Employment

  • Chair of Experimental and Clinical Toxicology, Saarland University, Homburg (Germany)
  • Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Homburg (Germany)

Education & Certification

  • PhD
  • M.Sc., Pharmacist
  • Clinical toxicologist, GTFCh

Professional Activities

  • Memberships in IADTMCT, TIAFT, GTFCh (German speaking society of forensic chemistry), DPhG (German society of pharmaceutical sciences)
  • Activities in IATDMCT: Vice chair young scientist committee, Member of communication commitee
  • Executive and committee positions held: TIAFT (Young scientist committee member), GTFCh (Chair of the continuous education program)
  • Number of publications: over 80 PubMed-listed and peer-reviewed articles, numerous book chapters
  • Speaking engagements: Several invited talks at international conferences (USA, Europe, Asia)
  • Professional appointments: Clinical toxicologist GTFCh

Molinaro Mariadelfina 150x200

Mariadelfina Molinaro
Pavia, Italy

[+] View Bio

She received the “Laurea” degree in Biological Science (MScBiol) in 1998, and the Post-graduate Diploma in General Pathology and in Pharmacology in 1992 and 2002, respectively at the University of Pavia (Italy). Since graduation, she was research fellow at the Department of Pharmacology of the Policlinico San Matteo of Pavia, where she became assistance manager in 1995. Since 2013 she is the head of the Laboratory of Clinical Pharmacology and TDM of the Clinical and Experimental Pharmacokinetics Unit at the Foundation IRCCS Policlinico San Matteo of Pavia.

She has been collaborating on national and international clinical and experimental trials on immunosuppressive drug therapy in different kind of transplants. She is currently the scientific research coordinator of projects on the role of intracellular concentrations of calcineurin inhibitors in the clinical management of patients undergoing transplantation, on the clinical pharmacokinetics of new biologics used in oncology and onco-hematology in adult and pediatric patients, and on the pharmacokinetics analysis of antiinfective drugs used in transplantation, onco-hematological adult and pediatric patients. She has been also the tutor of many MS and BS students.

She is member of the IATDMCT Society and the Anti-infective drug scientific committee, of the Society of Applied Pharmacology (SSFA) and of the Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC) which serves also as member of the scientific working group on TDM and personalized therapy.

She serves as a reviewer for international scientific journals and she has been delivering invited presentations at conferences and industrial workshops. She authored or coauthored scientific papers either published on international peer reviewed journals or presented at international conferences.


 Neely Michael 150x200

Michael Neely
Los Angeles, CA, USA

[+] View Bio

Employment

  • Acting Chief, Pediatric Infectious Diseases Division, Children's Hospital Los Angeles
    July 2016-Present
  • Associate Professor of Pediatrics, Clinical Scholar, University of Southern California Keck School of Medicine, Los Angeles, California
    September 2013- Present
  • Assistant Professor of Clinical Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California
    September 2002-2013

Education & Certification

  • “Pharmacokinetics and Pharmacogenomics of Once Daily Raltegravir and Atazanavir in Healthy Volunteers”, Master’s Degree in Clinical and Biomedical Investigations, University of Southern California, Los Angeles, CA, Awarded May 2011
  • Subspecialty Fellowships, Rainbow Babies and Children’s Hospital, University Hospitals of Cleveland, Division of Pediatric Infectious Diseases and Division of Pediatric Pharmacology, Cleveland, OH, July 1999 – June 2002
  • Pediatric Internship and Residency, Rainbow Babies and Children’s Hospital, University Hospitals of Cleveland, Cleveland, OH,  June 1996 –  June 1999
  • Doctorate of Medicine (MD), University of California, Davis, California, September 1992- June 1996
  • B.A. in Neurobiology (Highest Distinction Honors), University of California, Berkeley, 1991

Professional Activities

Society Memberships and Activities

  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
    • Member, 2006-current
    • Anti-infective drug committee
      • Founding Member, 2013-current
      • Vice-Chair, 2013-2015
      • Chair, 2015-current
    • Pharmacometrics Committee
      • Member, 2010-current
    • Journal of TDM Editorial Board, 2009-current
    • IATDMCT Sponsored or Endorsed Speaker
      • “Population Modeling with Pmetrics”, Christian Medical College, Vellore, Tamil Nadu, India, July 21-24, 2014
      • “Parametric and nonparametric dose optimization. Which is the best approach?”, University of Antioquia, Medellín, Colombia, November 7, 2014
      • “Population Modeling with Pmetrics”, Feevale University, Novo Hamborgo, Brazil, November 10-11, 2014
      • “5th Annual Individualized Therapeutic Approach Group” meeting, Lyon, France, April 13-15, 2016
      • “Pmetrics and BestDose” – University of Queensland, Brisbane, Australia, 2.5-day workshop, October 13-15, 2016
      • “The future of vancomycin dosing: pharmacometrics and AUCs”, St. Vincent’s Hospital, Sydney, Australia, October 17, 2016
      • “Antibacterial Therapy: Important Considerations for the Future” and “Pharmacometrics - Pmetrics and Best Dose Programs”, invited lectures at the IATDMCT Regional Meeting, 2nd National Symposium on Therapeutic Drug Monitoring, Christian Medical College, Vellore, Tamil Nadu, India, July 11-13, 2017
  • American College of Clinical Pharmacology (ACCP)
    • Member, 2002-current
    • Elected as a Fellow, 2011
    • Regent, 2013-current (term ends 2018)
    • Finance Committee Chair, 2017-current
    • Scientific co-Chair, Annual Meeting of the American College of Clinical Pharmacology, San Francisco, CA, September 2015
  • International Society of Pharmacometrics (ISOP)
    • Founding Member, 2011-current
    • Invited speaker: "Nonparametric modeling: what can it do?", ISOP Regional Event, Deerfield, IL, November 3, 2015
    • Inaugural Chair of the Steering Committee and co-Founder of the Clinical Pharmacometrics Special Interest Group
  • Society for Pediatric Research, elected December 2011

Current Peer-Reviewed Publications: 105

Current Research Funding

“Oral Dissolving Strips for the Delivery of Isoniazid in Children and Adults”

NIH-NIAID, SBIR BioD CAN # 16-8477185
PI: Ed Maliski (Oak Pharmaceuticals)
Role: Co-Investigator (5% FTE)

“Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy”
NIAID-NIH, SBIR 1R43AI125060-01
7/1/16 to 6/60/17
PI: Hal Ebitino (Biovinc)
Role: Co-Investigator (0% FTE)

"Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis"
NIH-NIAID, P01 AI123036
9/1/16 to 8/31/21
PI: George Drusano (University of Florida)
Role: Mathematical Modeling Core Co-Director, 5% FTE

"Optimizing Combination Therapy for Hepatitis C Virus with Pharmacodynamic Models"
NIH-NIAID, R01 AI111970
3/5/14 to 8/1/17
PI: Ashley Brown (University of Florida)
Role: Co-investigator, 5% FTE

“Population Pharmacokinetic Modeling and Dual Optimal Control”
NIH-NIGMS, R01 GM068968
9/01/12 to 08/31/17
PI: Michael Neely, MD, 30% FTE

“Ontogeny of Voriconazole Pharmacokinetics and Metabolism”
NIH-NICHD, R01 HD070886
6/1/12 to 2/1/18
PI: Michael Neely, MD, 30% FTE

Pending Research Funding

“Sequestration and Deactivation of Anthracycline by Adipocytes in the Leukemia Microenvironment”.
NIH-NICHD, R01 CA213129
7/1/17 to 6/30/22
co-PI: Michael Neely, MD, 15% FTE

Recent Invited Talks (Two Years)

  1. “Scalpels not Hammers: Precision Medicine in Infectious Diseases”, Infectious Diseases Grand Rounds, LAC+USC Medical Center, March 13, 2015
  2. "4th Annual Individualized Therapeutic Approach Group”, Limoges, France, April 28-30, 2015
  3. "Multiple Model Dose Optimization", Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, September 18, 2015
  4. "Antifungal TDM in the Clinic", Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, September 20, 2015
  5. "Introduction to R", American College of Clinical Pharmacology Annual Meeting, San Francisco, CA, September 27, 2015 (all-day workshop)
  6. "Do we need models to predict drug behavior?", International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Rotterdam, NL, October 15, 2015
  7. "TDM in critically ill patients: problems and solutions", International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Rotterdam, NL, October 16, 2015
  8. "Nonparametric pharmacometrics", University of Erasmus, Rotterdam, NL, October 17, 2015
  9. "Nonparametric modeling: what can it do?", International Society of Pharmacometric Regional Event, Deerfield, IL, November 3, 2015
  10. "Multiple model Bayesian adaptive control – optimizing individual therapy", Astellas Pharmaceuticals, Inc, Deerfield, IL, November 4, 2015
  11. "Population Modeling", University of Antioquia, Medellín, Colombia, November 10, 2015
  12. "Drug therapy in critically ill patients: problems and solutions ", University of Antioquia, Medellín, Colombia, November 11, 2015
  13. "Scalpels not sledgehammers: precision medicine for my patients", American Physician Scientists Association, 2015 West Regional Meeting, November 14, 2015
  14. "Introduction to Pmetrics and BestDose", American College of Clinical Pharmacology Gator Student Chapter, University of Florida, Gainesville, FL, February 4-5, 2016
  15. “5th Annual Individualized Therapeutic Approach Group”, Lyon, France, April 13-15, 2016
  16. "Multiple Model Adaptive Bayesian Control – Optimizing Individual Therapy", USC School of Pharmacy, April 25, 2016
  17. “Non-parametric modeling with Pmetrics” – University of Antioquia, Medellin, Colombia, July 18, 2016
  18. “Pmetrics and BestDose” – University of Queensland, Brisbane, Australia, 2.5-day workshop, October 13-15, 2016
  19. “The future of vancomycin dosing: pharmacometrics and AUCs”, St. Vincent’s Hospital, Sydney, Australia, October 17, 2016
  20. “The future of vancomycin dosing: prospective study of AUC-guided dosing”, Los Angeles Pediatric Infectious Diseases Citywide, Los Angeles, CA, April 12, 2017

Recent Visiting Scholars (Two Years)

  1. Nuria Padulles, PhD, Pharmacy Department, Hospital Universitari de Bellvitge, Barcelona , February 1 – March 31, 2015
  2. Binu Philip, MD, Professor of Pharmacology, Christian Medical College, Vellore, India, March 9 – April 10, 2015
  3. Michael Philippe, PhD candidate, University of Lyon, France, March 15 – October 31, 2015
  4. Teresa Nabais, PhD, University of Montreal, September 7 – November 6, 2015
  5. Jan Strojil, MD, PhD, Fulbright Scholar, Palacký University, Olomouc, Czech Republic, September 1, 2015 – April 30, 2016
  6. Pieter Glerum, MSc, Medicines Evaluation Board, Utrecht, NL, October 15, 2015 – February 28, 2016
  7. Teresa Nabais, PhD, University of Montreal, July 12 – September 23, 2016
  8. Dzhem Farandzha, Medical Student, Department of Pharmacology and Clinical Pharmacology, Sofia University, Sofia, Bulgaria, February 18 – March 5, 2017
  9. Femke de Velde PharmD, PhD, Pharmacy, Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands, March 20 – April 14, 2017

 Stove Christophe 150x200

Christophe Stove
Ghent, Belgium

[+] View Bio

Employment

  • PhD student
    • 1999-2003 Ghent University (Faculty of Medicine & Health Sciences)
  • Postdoctoral researcher
    • 2004-2007 Ghent University (Faculty of Sciences)
    • 2007-2013 Ghent University (Faculty of Pharmaceutical Sciences)
  • Assistant-Professor (‘Docent’)
    • Since Feb 2013 Ghent University (Faculty of Pharmaceutical Sciences)

Education & Certification:

  • 1999 Pharmacist
  • 2004 PhD in Medical Sciences

Professional Activities:

Activities specifically related to IATDMCT

  • Meetings:
    • First meeting in Stuttgart in 2011
    • Prize for best poster/poster presentation at the 2011 meeting
    • Participated to the 2013 and 2015 meetings (always with an active contribution (oral and/or poster)
    • Will participate to the 2017 meeting
  • Alternative Sampling Strategies Committee:
    • Member since 2011
    • Chair from 2011-2015
    • Vice-chair since 2015
    • Actively engaged in:
      • Organising workshops, roundtables, scientific sessions, etc. for the International Congresses in Salt Lake City, Rotterdam and Kyoto
      • Providing contributions to the Compass on a regular basis
  • Organizer of a successful IATDMCT Satellite Symposium in 2015
    • Alternative Sampling Strategies in Toxicology and Therapeutic Drug Monitoring
    • 176 registrants from 22 countries
    • [insert bio image here]
  • Young Scientist member
    • Active member since the start of membership
    • Co-represented young scientists at the 2015 meeting of the Japanese Society of Therapeutic Drug Monitoring
  • Referee for the journal Therapeutic Drug Monitoring
  • Core research activities align very well with the scope of IATDMCT

Teaching activities
Responsible for the following courses at Ghent University:

  • Toxicology (2nd Master)
  • General Toxicology (3rd Bachelor)
  • Bioanalysis (Master)
  • Chemical Criminalistics (Master)
  • Drug Toxicity (Master)
  • Supplements in Toxicology: advanced studies (MaNaMa Clinical Biology)
  • Co-responsible for Bioanalytical Practical Course

Research Activities (general):

  1. Publications: Summary:
    • 77 A1 articles published or in press; 2 proceedings; 1 Book as Editor, 4 Book Chapters
    • # (%) in different quartiles: Q1: 66% – Q2: 29% – Q3: 4% – Q4: 1%
      Average positioning: 20% - Median positioning: 18%
      # in top 10%: 20 (26%) - # in top 5 of a category: 14 (18%)
    • 51 articles as 1st, 2nd or last author
    • 1186 Times Cited (ISI Web of Knowledge → Web of Science, 01/03/2017)
    • Average Impact Factor: 4.497; Median Impact Factor: 3.436
    • h-index (# articles with # of citations): 21
  2. Promotor of 4 defended PhD’s and >10 ongoing PhD’s
  3. 3 main research lines can be distinguished:
    • Alternative sampling strategies (e.g. dried blood microsampling, hair analysis)
    • Development of bio-assays for monitoring of activation of G-protein coupled receptors
    • Analysis of vitamers (amongst which folates), their precursors and degradation products, in plant material and biological material (blood)
  4. Referee for > 30 journals (currently about 1 review/week)
  5. Involved in the activities (e.g. regional editor; member of scientific committees) of main international scientific organisations (e.g. TIAFT and IATDMCT); Former chair of the Alternative Sampling Strategies Committee of IATDMCT.
  6. Organizer of intra-faculty conferences, as well as an international conference on “Alternative Sampling Strategies in Toxicology and Therapeutic Drug Monitoring” (Sep 2014, 176 registrants). Main co-organizer of the TIAFT2018 meeting, to be held in August 2018 in Ghent (anticipated number of attendants: 600-700).
  7. > 100 oral and poster presentations at national and international conferences
  8. Member of the reading or examination committee of >30 PhD theses (national & international)
  9. Member of scientific societies:
    • Toxicological Society of Belgium and Luxemburg (BLT) (Board Member);
    • BelTox (Belgian Society of Toxicology and Ecotoxicology);
    • Belgian Environmental Mutagen Society (Board Member);
    • Belgian Society of Mass Spectrometry (BSMS);
    • American Chemical Society (ACS);
    • The International Association of Forensic Toxicologists (TIAFT);
    • International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT);
    • Belgisch Genootschap voor Farmaceutische Wetenschappen (BGFW);
    • Belgisch Genootschap voor Gerechtelijke Geneeskunde (BGGG).

Service Activities (external):

  • Head of the Laboratory of Forensic Toxicology
    • Follow-up of routine casework in judicial cases since Jan 1st 2008
    • End responsible (lab director) since Sept 15, 2014
    • Provided many hundreds of reports to the Department of Justice
    • Expert witness in court
  • Core member of the Forensic Institute of Ghent University (FI-UGent).
  • Toxicological consultancy; ad hoc toxicological expertise (e.g. Superior Health Council, Fonds Medische Ongevallen).
  • Involved in providing toxicological expertise in the train disaster at Wetteren (Belgium) (May 2013 - on-site expertise, scientific publications, part of the superior health council, report to federal minister of public health, …).
  • Recognized by the Department of Justice as expert for determination of alcohol in cases of drunk driving (since Sept 4, 2014).
  • Director of the ISO 17025/1595 accredited Reference Laboratory Ref4U, implementing reference measurement procedures for e.g. thyroid hormones and vitamin D.

Wieland Eberhard 150x200

Eberhard Wieland
Stuttgart, Germany

[+] View Bio

Employment

  • 2007-present , Medical Director Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart and Professor of Clinical Chemistry and Laboratory Medicine, Eberhard-Karls-University Tuebingen, Germany
  • 2003-2007, Medical Director Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart and Professor of Clinical Chemistry, Department of Clinical Chemistry, Georg-August University-Goettingen, Germany
  • 2000-2003, Senior physician and Professor of Clinical Chemistry, Department of Clinical Chemistry Georg-August-University Goettingen, Germany
  • 1996-2000, Senior physician Department of Clinical Chemistry, Georg-August-University Goettingen, Germany
  • 1987-1996, Resident Clinical Chemistry and Laboratory Medicine, Georg-August-University Goettingen, Germany
  • 1985-1987, Fellow Department of Endocrinology and Metabolism, University of California San Diego (UCSD), USA
  • 1984-1985, Resident Medical Microbiology, Ruprecht-Karls.-University Heidelberg, Germany
  • 1983-1984, Resident Internal Medicine, Ruprecht-Karls-University Heidelberg, Germany

Education & Certification

  • 1997 Habilitation Georg-August-University of Göttingen, Germany
  • 1982 Thesis and Doctorate in Biochemistry (MD), Ruprecht-Karls-University of Heidelberg, Germany
  • 1976-1982 Medical Education, Ruprecht-Karls-University, Heidelberg, Germany
  • 1968-1976 Kurfuerst Friedrich Academic High School, Heidelberg, Germany
  • 1967-1968 Rabanus Maurus Academic High School, Mainz, Germany
  • 1963-1976 Ludwig Schwamb Elementary School, Mainz, Germany

Professional Activities

Professional Registrations

  • 2013 Fellow European Board of Laboratory Medicine/Medical Biopathology (FEBLM/MB).  European Union of Medical Specialists (UEMS)
  • 2005 European Specialist in Clinical Chemistry (EuSpLM) European Federation of Laboratory Medicine (EFLM)
  • 1993 Clinical Chemist, Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin
  • 1993 Clinical Pathology Consultant, German Medical Chamber

Professional Society Memberships

  • International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)
  • American Association for Clinical Chemistry (AACC)
  • American Heart Association (AHA)
  • Berufsverband Deutscher Laborärzte (BDL)
  • European Atherosclerosis Society (EAS)
  • Gesellschaft Deutscher Naturforscher und Ärzte (GDNA)
  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
  • Society For Free Radical Research (SFRR)
  • Transplantation Society (TTS)
  • Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL)

Activities in IATDMCT:

  • Member Immunosuppressive Drugs Committee
  • Member Biomarkers Committee
  • Member Communications Committee
  • 2011-2015, Director of Education
  • 2011 Chair organizing committee 12th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Stuttgart, Germany

Advisory Board Memberships:

  • Chair Scientific Program Committee 4th Joint EFLM-UEMS Congress "Laboratory Medicine at the Clinical Interface", Warsaw 2016
  • President of the Board, Section of Medical Biopathology, European Union of Medical Specialists (UEMS)
  • Chair Commission for Good Laboratory Practice (GLP) Association Medical Laboratory Diagnostics (AML)
  • Chair Working Group Laboratory Accreditation Vereinte Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL)
  • Auditor ISO 17025 and 15189 Deutsche Akkreditierungsstelle GmbH (DAkkS)
  • Delegate sectoral Committee Medical Laboratories (ISO 15189) DAkkS

Journal Editorial Boards:

  • Therapeutic Drug Monitoring
  • Clinical Biochemistry, Canada
  • Clinical Laboratory, Germany
  • Journal of Laboratory Medicine, Germany
  • Folia Medica, Plovdiv, Bulgaria

Honours:

  • Elected full member Bulgarian Academy of Sciences and Arts (BSAA)

Publications:

  • 122 publications listed in PubMed
  • 11 book chapters
  • >70 invited lectures